Antifungal compounds: controversies, queries and conclusions

References

• Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26: 1383–1396.
   PubMed Web of Science ®Google Scholar
• Chopra R, Blair S, Strang J, Cervi P, Patterson KG, Goldstone AH. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenicpatients.J Antimicrob Chemot her 1991; 28 (Suppl. B): 93–104.
   Google Scholar
• Noskin G, Pietrelli L, Gurith M. Amphotericin B colloidal dispersion in bone marrow transplantation. Ninth International Symposium on Infections in the Immunocompromised Host. 1996.
   Google Scholar
• de Marie S, Janknegt R, Bakker-Woud enb erg IAJM. Clinical useof liposomal and lipid-complexekl amphotericin B. J Antimicrob Chemother 1994; 33: 907–916. 0 2000 ISHAM, Medical Mycology, 38, Suppl. I, 323-333
   Google Scholar
• Jangnegt R, de Marie S, Bakker-Woudenberg IAJM, Crommelin DJA Liposomal and lipid formulations of amphotericin B. Clin Pharmacokinet 1995; 23: 279–291.
   Web of Science ®Google Scholar
• Meunier F, Prentice HG, Ringden O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother 1991; 28 (Suppl. B): 83–91.
   Google Scholar
• White MH, Bowden RA, Sandler ES, et al. Randomized double-blind clinical trial of amphotericin B colloidal dispersion vs amphotericin B in the empirical treatment of fever and neutrope-nia. Clin Infect Dis 1998; 27: 296–302.
   PubMed Web of Science ®Google Scholar
• Powles R, Mawhorter S, Williams T. Liposomal nystatin (Ny-otran) vs amphotericin B (Fungizone) in empiric treatment of presumed fungal infection in neutropenic patients. 39th Inter-science Conference on Antimicrobial Agents and Chemotherapy. 1999; Abstract LB–4.
   Google Scholar
• Goodwin SD, Cleary JD, Walawander CA, Taylor JW, Grasela THJr. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infect Dis 1995; 20: 755–761.
   Google Scholar
• Gurwith M, Mamelok R, Pietrelli L, Du M. Renal sparing by amphotericin B colloidal dispersion: Clinical experience in 572 patients. Chemotherapy 1999; 45: 39–47.
   PubMed Web of Science ®Google Scholar
• Fleming R, Kantarjian H, Husni R, et al. Randomized study of two lipid formulations of amphotericin B in the treatment of suspected or documented fungal infections in patients with leukemia. Focus on Fungal Infections. 1999; Abstract 38.
   Google Scholar
• Caillot D, Casanovas O, Solary E. Efficacy and tolerance of an amphotericin B lipid (Intralipid) emulsion in the treatment of candidemia in neutropenic patients. J Antimicrob Chemother 1993; 31: 161–169.
   Google Scholar
• Sorkine P, Nagar II, Weinbroum A. Administration of ampho-tericin B in lipid emulsion decreases nephrotoxicity. Results of a prospective controlled study in critically ill patients. Grit Care Med 1996; 24: 1311–1315.
   Google Scholar
• Wong-Beringer A, Jacobs R, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27: 603–618.
   PubMed Web of Science ®Google Scholar
• Mills W, Chopra R, Linch DC, Goldstone AH. Liposomal amphotericin B in the treatment of fungal infections in neu-tropenic patients: a single-centre experienceof 133 episodes in 116 patients. Br J Haematol 1994; 86: 754–760.
   PubMed Web of Science ®Google Scholar
• Severens JL, Donnelly JP, Meis JFGM, DeVries Robbe PF, De Pauw B, Verweij PE. Two strategies for managing invasive aspergillosis: a decision analysis. Clin Infect Dis 1998; 25: 1148–1154.
   Google Scholar
• Hamill RJ, Sobel J, El-Sadr W, et al. Randomized double-blind trial of AmBisome (liposomal amphotericin B) and amphotericin B in acute cryptococal meningitis in AIDS patients. 39th Inter-science Conference on Antimicrobial Agents and Chemotherapy. 1999; Abstract 1161.
   Google Scholar
• Anaissie El, White M, Uzun O, et al. Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and disseminated candidiasis. 35th International Conference on Antimicrobial Agents and Chemotherapy. 1995; Abstract 330.
   Google Scholar
• White M, Anaissie El, Kusne S. Amphotericin B colloidal dispersion versus amphotericin B as therapy for invasive asper-gillosis. Clin Infect Dis 2001; (in press).
   Google Scholar
• Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764–771.
   PubMed Web of Science ®Google Scholar
• Tollemar J. Fungal infections in solid organ transplant recipients.In: Bowden R, Ljungman P, Paya C, eds. Transplant Infections Transplantation. Philadelphia: Lippincott-Raven Publishers, 1998: 339–350.
   Google Scholar
• Prentice HG, Hahn IM, Herbrecht R, et al. A randomized comparison of liposomal amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haema-tol 1997; 9& 711–718.
   Google Scholar
• Leenders AC, Daenen S, Jansen RL, et al. Liposomal ampho-tericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. BMJ 1998; 103: 205–212.
   Google Scholar
• Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis 1999; 1& 702–708.
   Google Scholar
• Noskin G, Pietrelli L, Gurwith M, et al. Treatment of invasive fungal infections with amphotericin B colloidal dispertion in bone marrow transplant recipients. Bone Marrow Transpl 1999; 23: 697–703.
   PubMed Web of Science ®Google Scholar
• Persson U, Ragnarsson TG, Andersson S, et al. Cost-effective-ness analysis of treatment with liposomal amphotericinB versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. Pharmaco Economics 1992; 2: 500–508.
   PubMedGoogle Scholar
• Boogaerts M, Tormans G, Maes E, et al. Cost-effictiveness analysis of AmBisome vs amphotericin B in the empiric treatment of febrile neutropenia in adults and children. Blood 1996; 88: 501a.
   Web of Science ®Google Scholar
• Gupta AK, Katz I, Shear NH. Drug interactions with itracona-zole, fluconazole and terbinafme and their management.Am Acad Dermatol 1999; 41: 237–245.
   Google Scholar
• Beyer J, Schwartz S, Heinemann V, Siegert W. Strategies in prevention of invasive pulmonary aspergillosis in immunosup-pressed or neutropenic patients. Antimicrob Agents Chemother 1994; 38: 911–917.
   PubMed Web of Science ®Google Scholar
• Rousey SR, Russler M, Gottlieb M, Ash RC. Low-dose ampho-tericin B prophylaxis against Aspergillus infection in allogenic BMT. Am J Med 1991; 91: 484–492.
   PubMed Web of Science ®Google Scholar
• Tollemar J, Höckerstedt K, Ericzon B-G, Jalanko H, Ringdén 0. Prophylaxis with Liposomal Amphotericin B (AmBisome) prevents fungal infection in liver transplant recipients: Long-term results of a randomised, placebo-controlled trial. 1195-1198.
   Google Scholar
• Kline S, Larsen TA, Fieber L, et al. Limited toxicity of prolonged therapy with high doses of Amphotericin B lipid complex. Clin Infect Dis 1995; 21: 1154–1158.
   PubMed Web of Science ®Google Scholar
• Kauffman CA, Wiseman SW. Anaphylaxis upon switching lipid containing amphotericin B formulations. Clin Infect Dis 1998; 26: 1237–1238.
   PubMed Web of Science ®Google Scholar
• Richardson MD, Kokki MH. Diagnosis and prevention of fungal infection in the immunocompromiseid patient. Blood Rev 1998; 12-. 241–254.
   Google Scholar
• Kern W, Behre G, Rudolf T, et al. Failure of flucoanzole prophylaxis to reduce mortality of the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukaemia: results of a prospective randomised phase III study. Cancer 1998; 83: 291–301.
   PubMed Web of Science ®Google Scholar
• Krcmer J, Mateicka F, Kunova A, et al. Hematogenous tri-chosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazole. Support Care Cancer 1999; 7: 39–43.
   PubMed Web of Science ®Google Scholar
• Grubbins PO, Bowman JL, Penzak SR. Antifungal prophylaxis to prevent invasive mycoses among bone marrow transplantation recipients. Pharmacotherapy 1998; 18: 549.
   Google Scholar
• Scharfstein JA, Paltiel D, Freedberg KA. The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infection in AIDS patients. Med Decision Making 1997; 17: 373–381.
   Google Scholar
• Lecciones JA, Lee JW, Navarro E, et al. Vascular catheter-asso-ciated fungemia in cancer patients: analysis of 155 episodes. Rev Infect Dis 1992; 14: 875–883.
   Google Scholar
• Pannuti CS, Gingrich R, Pfaller MA, Kao C, Wenzel RP. Nosocomial pneumonia in patients having bone marrow trans-plant. Attributable mortality and risk factors. Cancer 1992; 69: 2653–2662.
   Google Scholar
• Vartivarian SE, Anaissie El, Bodey GP. Emerging fungal patho-gens in immunocompromiseid patients: classification, diagnosis, and management. Clin Infect Dis 1993; 17 (Suppl. 2): S487–S491.
   Google Scholar
• Walsh TJ, Hier DB, Caplan LR. Fungal infections of the central nervous system: analysis of risk factors and clinical manifesta-tions. Neurology 1985; 35: 1654–1657.
   Google Scholar
• Fasano C, O'Keeffe J, Gibbs D. Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents. Eur J Clin Microbiol Infect Dis 1994; 13: 351–354.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Hiemenz J, Pizzo PA. Evolving risk factors for invasive fungal infections: all neutropenic patients are not the same (editorial). Clin Infect Dis 1994; 18: 793–798.
   Google Scholar
• Walsh TJ, Lee JVV. Prevention of invasive fungal infections in patients with neoplastic diseases. Clin Infect Dis 1993; 17: S468–480.
   Web of Science ®Google Scholar
• Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empirical antibiotic and antifungal therapy for cancer patients with pro-longed fever and granulocytopenia.AmJ Med 1982; 72:101–111.
   PubMed Web of Science ®Google Scholar
• EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989; 86: 668–672.
   Google Scholar
• Walsh TJ, Lee J, Lecciones J, et al. Empiric therapy with amphotericin B in febrile granulocytopenic patients. Rev Infect Dis 1991; 13: 496–503.
   PubMedGoogle Scholar
• Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845–851.
   PubMed Web of Science ®Google Scholar
• Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk El, Cassileth PB. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984; 100: 345–351.
   PubMed Web of Science ®Google Scholar
• Pizzo PA. After empiric therapy. What to do until the granulo-cyte comes back. Rev Infect Dis 1987; 9: 214–219.
   Google Scholar
• Schwartz RS, Mackintosh FR, Schrier SL, Greenberg PL. Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myeloge-nous leukemia. Cancer 1984; 53: 411–419.
   PubMed Web of Science ®Google Scholar
• Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unex-plained fever. A statement by The Infectious Disease Society of America. J Infect Dis 1990; 161: 381–396.
   PubMed Web of Science ®Google Scholar
• Guiot HFL, Fibbe WE, van't Wout J. Risk factors for fungal infection in patients with malignant hematological disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis 1994.
   Google Scholar
• Bow El, Shore TB, Kilpatrick MG, Scott BA, Schacter B. Relationship of invasive fungal disease and high-dose cytarabine plus etoposide containing remission-induction regimens for acute myeloid leukemia. Blood 1991; 78 (Suppl.): 55A.
   Google Scholar
• Walsh TJ, Lee J, Aoki S, et al. Experimental basis for usage of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts. Rev Infect Dis 1990; IL/ S307-S317. @ 2000 ISHAM, Medicd Mycology, 38, Suppl. I, 323–333
   Google Scholar
• Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow trans-plantation: a prospective, randomized double blind study. J Infect Dis 1995; 171: 1545–1552.
   PubMed Web of Science ®Google Scholar
• Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323–1332.
   PubMed Web of Science ®Google Scholar
• Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unex-plained fever. Clin Infect Dis 1997; 25: 551–573.
   PubMed Web of Science ®Google Scholar
• Powderly W, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syn-drome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 1992; 326: 793–798.
   PubMed Web of Science ®Google Scholar
• Supparatpinyo K, Perriens J, Nelson KE, Sirisanthana T. A controlled trial of itraconazole to prevent relapse of Penicillium marneffei infection in patients infected with the human im-munodeficiency virus. N Engl J Med 1998; 339: 1739–1743.
   PubMed Web of Science ®Google Scholar
• Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Prevention of corticosteroid-induced suppression of human polymorphonu-clear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and interferon-7. Infect Immun 1993; 61: 4870–4877.
   Google Scholar
• Roilides E, Blake C, Holmes A, Pizzo PA, Walsh TJ. Granulo-cyte-macrophage colony-stimulating factor and interferon-7 pre-vent dexamethasone-induced imunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J Med Vet Mycol 1996; 34: 63–69.
   Google Scholar
• Roilides E, Holmes A, Blake C, Pizzo PA, Walsh TJ. Effects of granulocyte colony-stimulating factor and interferon-7 on anti-fungal activity of human polymorphonuclearneutrophils against pseudohyphae of different medically important Candida species. J Leukoc Biol 1995; 57: 651–656.
   Google Scholar
• Roilides E, Dimitriadou A, Kadiltsoglou I, et al. IL-10 exerts suppressive and enhancing effects on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Im-munol 1997; 158: 322–329.
   PubMed Web of Science ®Google Scholar
• Cenci E, Mencacci A, Del Sero G, et al. Interleukin-4 causes susceptibility to invasive aspergillosis through suppression of protective type 1 responses. J Infect Dis 1999; 180: 1957-1968.
   Google Scholar
• Kullberg BJ, van der Meer JW, Meis JF, Keuter M, Curls JH, Netea MG. Recombinant murine granulocyte colony-stimulating factor protects against acute disseminated Candida albicans infection in nonneutropenic mice. J Infect Dis 1998; 177: 175–181.
   PubMed Web of Science ®Google Scholar
• Mayer P, Schutze C, Lam C, Kricek F, Liehl E. Recombinant murine granulocyte-macrophage colony-stimulating factor aug-ments neutrophil recovery and enhances resistance to infections in myelosuppressekl mice. J Infect Dis 1991; 163: 584–590.
   Google Scholar
• Cenci E, Bartocci A, Puccetti P, Mocci S, Stanely ER, Bistoni F. Macrophage colony-stimulating factor in murine candidiasis: Serum and tissue levels during infection and protective effect of exogenous administration. Infect Immun 1991; 59: 868–872.
   PubMed Web of Science ®Google Scholar
• Polak-Wyss A. Protective effect of human granulocyte colony-stimulating factor on Cryptococcus and Aspergillus infections in normal and immunosuppressekl mice. Mycoses 1991; 34: 205–215.
   PubMed Web of Science ®Google Scholar
• Graybill JR, Bocanegra R, Najvar LK, Loebenberg D, Luther MF. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob Agents Chemother 1998; 42: 2467–2473.
   Google Scholar
• Walsh T, Gonzalez C, Lyman C, et al. Human recombinant macrophage colony stimulating factor (M-CSF) augments pul-monary host defense against Aspergillus fumigatus. Abstracts of the Annual Meeting of the American Society of Microbiology, 1994; Abstract F–27.
   Google Scholar
• Mehrad B, Strider RM, Standiford TJ. Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. J Immunol 1999; 162: 1633–1640.
   Google Scholar
• Muranaka H, Suga M, Nakagawa K, Sato K, Gushima Y, Ando M. Effects of granulocyte and granulocyte-macrophagecolony-stimulating factors in a neutropenic murine model of tri-chosporonosis. Infect Immun 1997; 65: 3422–3429.
   PubMed Web of Science ®Google Scholar
• A control trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Gran-ulomatous Disease Cooperative Study Group. N Engl J Med 1991; 324: 509–516.
   PubMed Web of Science ®Google Scholar
• Aviles A, Guzman R, Garcia EL, Talavera A, Diaz-Maqueo JC. Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anti-Cancer Agents 1996; 7: 392–397.
   Google Scholar
• Nemunaitis J, Buckner CD, Dorsey KS, Willis D, Meyer W, Appelbaum F. Retrospective analysis of infectious disease in patients who receive recombinant human granulocyte-macrophage colony-stimulating factor versus patients not receiv-ing a cytokine who underwent autologous bone marrow transplantation for treatment of lymphoid cancer. Am J Clin Oncol 1998; 21: 341–346.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Anderson JVV, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients ( > 55 to 70 years) with acute myelogenous leukemia: a study by the Eastern Cooperative Oncology Group (El 490). Blood 1995; 86:457–462.
   PubMed Web of Science ®Google Scholar
• Rowe JM. Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections. Clin Infect Dis 1998; 26: 1290–1294.
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Shannon-Dorcy K, Appelbaum FR, et al. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor. Blood 1993; 82: 1422–1427.
   PubMed Web of Science ®Google Scholar
• Ohno R, Miyawaki S, Hatake K, et al. Human urinary macrophage colony-stimulating factor reduces the incidence and duration of febrile neutropenia and shortens the period required to finish three courses of intensive consolidation therapy in acute myeloid leukemia: a double-blind controlled study. J Clin Oncol 1997; 15: 2954–2965.
   PubMed Web of Science ®Google Scholar
• Vora S, Purimetla N, Brummer E, Stevens DA. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 1998; 42: 907–910.
   PubMed Web of Science ®Google Scholar
• Vora S, Chauhan S, Brummer E, Stevens DA. Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 1998; 42: 2299–2303.
   PubMed Web of Science ®Google Scholar
• Kuhara T, Uchida K, Yamaguchi H. Therapeutic efficacy of human macrophage colony-stimulating factor, used alone and in combination with antifungal agents, in mice with systemic Candida albicans infection. Antimicrob Agents Chemother 2000; 44: 19–23.
   Google Scholar